November 4, 2022

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).

We are pleased to enclose a Press Release as regards, receipt of tentative U.S. FDA approval for the Company’s Abbreviated New Drug Application for Drospirenone Tablets, 4 mg, to market a generic equivalent of Slynda® Tablets, 4 mg, of Exeltis USA Inc.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

Rajvardhan Vishnu Satam

R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)

Encl: a/a
Lupin Receives Tentative Approval from U.S. FDA for Drospirenone Tablets

Mumbai, Baltimore, November 04, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Drospirenone Tablets, 4 mg, to market a generic equivalent of Slynd® Tablets, 4 mg, of Exeltis USA Inc.

Drospirenone Tablets (RLD Slynd®) had estimated annual sales of USD 141 million in the U.S. (IQVIA MAT September 2022).

About Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 8.7% of its revenue in research and development in FY22.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.
Follow us on Twitter: https://twitter.com/LupinGlobal|LinkedIn: https://www.linkedin.com/company/lupin
Facebook: http://www.facebook.com/LupinWorld/

For further information or queries please contact –

Shweta Munjal
Vice President & Global Head – Corporate Communications
Email: shwetamunjal@lupin.com

*Safe Harbor Statement
Slynd® is a registered trademark of Chemo Research, S.L.